CONCLUSION
In this retrospective cohort, AZM-Corticosteroids and therapeutic anticoagulation, when indicated, represented a favorable combination for patients hospitalized with COVID-19, reducing mortality, length of hospitalization and the risk for MV. HCQ did not yield benefits to combination therapy and we do not support its use for inpatients. HFNC oxygen therapy was able to reduce the risk of MV support. Individuals older than >65 years, with presence of up one comorbidity, pulmonary involvement more than or equal to 50%, saturation <93%, lymphopenia, D-dimers and CRP elevated on arrival, and oxygen requirement through BiPAP or HFNC, ICU admission and MV during hospitalization represented the set of clinical predictors for worse prognosis.